Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases

BACKGROUND: Cancer immunotherapy is rapidly expanding but its clinical efficacy is hampered by immune related adverse events (ir-AE). There is a concern regarding patients with pre-existing auto-immune diseases (PAD) undergoing immunotherapy. METHODS: An electronic search was performed (Medline) to...

Descripción completa

Detalles Bibliográficos
Autores principales: Klavdianou, Kalliopi, Melissaropoulos, Konstantinos, Filippopoulou, Alexandra, Daoussis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693295/
https://www.ncbi.nlm.nih.gov/pubmed/34964025
http://dx.doi.org/10.31138/mjr.32.3.218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693295/
https://www.ncbi.nlm.nih.gov/pubmed/34964025
http://dx.doi.org/10.31138/mjr.32.3.218

Ejemplares similares